FDA approves additional strengths of SOLODYN for inflammatory lesions treatment
Links shared publicly online about this topic.
- 910total visits
FDA approves additional strengths of SOLODYN for inflammatory lesions treatment
Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
View full resource at news-medical.net
Tags: Acne, Diet and Nutrition, Drug, Pregnancy, FDA, News
Most Recently Shared on August 30, 2010 at 5:35 pm By:
Pregnancy News: FDA approves additional strengths of SOLODYN for inflammatory lesions treatment: Medicis today ann... http://bit.ly/a30UnM
Advertisement
